Andreas Beuchel, Dina Robaa, Dereje A. Negatu, Abdeldjalil Madani, Nadine Alvarez, Matthew D. Zimmerman, Adrian Richter, Lea Mann, Sophie Hoenke, René Csuk, Thomas Dick, Peter Imming*
{"title":"新型NBTI DNA螺旋酶抑制剂抗脓肿分枝杆菌哌啶-4-羧酰胺的构效关系","authors":"Andreas Beuchel, Dina Robaa, Dereje A. Negatu, Abdeldjalil Madani, Nadine Alvarez, Matthew D. Zimmerman, Adrian Richter, Lea Mann, Sophie Hoenke, René Csuk, Thomas Dick, Peter Imming*","doi":"10.1021/acsmedchemlett.1c00549","DOIUrl":null,"url":null,"abstract":"<p ><i>Mycobacterium abscessus</i> causes difficult-to-cure pulmonary infections. The bacterium is resistant to most anti-infective agents, including first line antituberculosis (anti-TB) drugs. MMV688844 (<b>844</b>) is a piperidine-4-carboxamide (P4C) with bactericidal properties against <i>M. abscessus</i>. We recently identified DNA gyrase as the molecular target of <b>844</b>. Here, we present <i>in silico</i> docking and genetic evidence suggesting that P4Cs display a similar binding mode to DNA gyrase as gepotidacin. Gepotidacin is a member of the Novel Bacterial Topoisomerase Inhibitors (NBTIs), a new class of nonfluoroquinolone DNA gyrase poisons. Thus, our work suggests that P4Cs present a novel structural subclass of NBTI. We describe structure–activity relationship studies of <b>844</b> leading to analogues showing increased antibacterial activity. Selected derivatives were tested for their inhibitory activity against recombinant <i>M. abscessus</i> DNA gyrase. Further optimization of the lead structures led to improved stability in mouse plasma and increased oral bioavailability.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"13 3","pages":"417–427"},"PeriodicalIF":4.0000,"publicationDate":"2022-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.1c00549","citationCount":"2","resultStr":"{\"title\":\"Structure–Activity Relationship of Anti-Mycobacterium abscessus Piperidine-4-carboxamides, a New Class of NBTI DNA Gyrase Inhibitors\",\"authors\":\"Andreas Beuchel, Dina Robaa, Dereje A. Negatu, Abdeldjalil Madani, Nadine Alvarez, Matthew D. Zimmerman, Adrian Richter, Lea Mann, Sophie Hoenke, René Csuk, Thomas Dick, Peter Imming*\",\"doi\":\"10.1021/acsmedchemlett.1c00549\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p ><i>Mycobacterium abscessus</i> causes difficult-to-cure pulmonary infections. The bacterium is resistant to most anti-infective agents, including first line antituberculosis (anti-TB) drugs. MMV688844 (<b>844</b>) is a piperidine-4-carboxamide (P4C) with bactericidal properties against <i>M. abscessus</i>. We recently identified DNA gyrase as the molecular target of <b>844</b>. Here, we present <i>in silico</i> docking and genetic evidence suggesting that P4Cs display a similar binding mode to DNA gyrase as gepotidacin. Gepotidacin is a member of the Novel Bacterial Topoisomerase Inhibitors (NBTIs), a new class of nonfluoroquinolone DNA gyrase poisons. Thus, our work suggests that P4Cs present a novel structural subclass of NBTI. We describe structure–activity relationship studies of <b>844</b> leading to analogues showing increased antibacterial activity. Selected derivatives were tested for their inhibitory activity against recombinant <i>M. abscessus</i> DNA gyrase. Further optimization of the lead structures led to improved stability in mouse plasma and increased oral bioavailability.</p>\",\"PeriodicalId\":20,\"journal\":{\"name\":\"ACS Medicinal Chemistry Letters\",\"volume\":\"13 3\",\"pages\":\"417–427\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2022-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.1c00549\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Medicinal Chemistry Letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acsmedchemlett.1c00549\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsmedchemlett.1c00549","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Structure–Activity Relationship of Anti-Mycobacterium abscessus Piperidine-4-carboxamides, a New Class of NBTI DNA Gyrase Inhibitors
Mycobacterium abscessus causes difficult-to-cure pulmonary infections. The bacterium is resistant to most anti-infective agents, including first line antituberculosis (anti-TB) drugs. MMV688844 (844) is a piperidine-4-carboxamide (P4C) with bactericidal properties against M. abscessus. We recently identified DNA gyrase as the molecular target of 844. Here, we present in silico docking and genetic evidence suggesting that P4Cs display a similar binding mode to DNA gyrase as gepotidacin. Gepotidacin is a member of the Novel Bacterial Topoisomerase Inhibitors (NBTIs), a new class of nonfluoroquinolone DNA gyrase poisons. Thus, our work suggests that P4Cs present a novel structural subclass of NBTI. We describe structure–activity relationship studies of 844 leading to analogues showing increased antibacterial activity. Selected derivatives were tested for their inhibitory activity against recombinant M. abscessus DNA gyrase. Further optimization of the lead structures led to improved stability in mouse plasma and increased oral bioavailability.
期刊介绍:
ACS Medicinal Chemistry Letters is interested in receiving manuscripts that discuss various aspects of medicinal chemistry. The journal will publish studies that pertain to a broad range of subject matter, including compound design and optimization, biological evaluation, drug delivery, imaging agents, and pharmacology of both small and large bioactive molecules. Specific areas include but are not limited to:
Identification, synthesis, and optimization of lead biologically active molecules and drugs (small molecules and biologics)
Biological characterization of new molecular entities in the context of drug discovery
Computational, cheminformatics, and structural studies for the identification or SAR analysis of bioactive molecules, ligands and their targets, etc.
Novel and improved methodologies, including radiation biochemistry, with broad application to medicinal chemistry
Discovery technologies for biologically active molecules from both synthetic and natural (plant and other) sources
Pharmacokinetic/pharmacodynamic studies that address mechanisms underlying drug disposition and response
Pharmacogenetic and pharmacogenomic studies used to enhance drug design and the translation of medicinal chemistry into the clinic
Mechanistic drug metabolism and regulation of metabolic enzyme gene expression
Chemistry patents relevant to the medicinal chemistry field.